BioFire Defense


BioFire Defense provides a comprehensive suite of biological agent identification products, including the BioFire® FilmArray® and RAZOR® Mk II Systems, aimed at the biodefense and first responder community. Their mission is to accelerate medical results, promote health, and enhance community security, making the world a safer and healthier place. As a subsidiary of bioMérieux, BioFire Defense is a leader in fast, easy-to-use, PCR-based molecular diagnostic and detection systems, enhancing the capability and readiness to protect armed forces, improve global health, and save lives.

BioFire Defense

BioFire Defense

79 West 4500 South, Suite 14, Salt Lake City, Utah 84107


What We Do

A fully automated biodetection system that identifies dozens of lethal viruses and bacteria, including emerging infectious diseases, using a closed system with automated capabilities.

A compact, lightweight field PCR unit designed for first responders and military troops, using cutting-edge PCR technology to detect and identify biological agents quickly and reliably.

BioFire Defense supplies identification systems and test kits for rapid identification and diagnostic confirmation of biological warfare agents for the U.S. Military and other national agencies.

These panels test for a variety of viruses, bacteria, and protozoa, providing fast results for biodefense and biosurveillance applications.

Ready-to-use, freeze-dried test kits for detecting and identifying pathogens and biothreat agents, optimized for the RAZOR instruments.

A qualitative, multiplexed, nucleic acid based test for the simultaneous detection and identification of multiple bacterial, viral, and protozoan nucleic acids directly from whole blood, providing results in under an hour.

A nested multiplexed RT-PCR test for the qualitative detection of SARS-CoV-2 RNA, providing results in about 45 minutes.



News & Updates

BioFire Defense will exhibit at the APHL 2025 conference in Portland, OR, showcasing their products and solutions.

An article discussing the development of the BioFire® COVID-19 Test and the introduction of the Coronavirus Monitoring for Inclusivity Tool (CoMIT) to address scalability and accuracy in testing.